<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778046</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00106221</org_study_id>
    <nct_id>NCT04778046</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension SOLAR</brief_title>
  <acronym>PH SOLAR</acronym>
  <official_title>Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bastiaan Driehuys</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to develop a noninvasive signature for pulmonary vascular&#xD;
      remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging&#xD;
      (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies.&#xD;
      PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked&#xD;
      a pathologic &quot;ground truth&quot; correlate of these signatures, which could be provided by&#xD;
      comparing them with the pathology of lung explant tissue from patients who have undergone a&#xD;
      lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in&#xD;
      future studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to identify a 129Xe MRI signature associated with PAH-like&#xD;
      pulmonary vascular remodeling, consisting of plexiform arteriopathy, smooth muscle cell&#xD;
      proliferation, and vascular fibrosis, in IPF and COPD that could be used to identify&#xD;
      potential responders vs non-responders to PAH-specific therapies. The central hypothesis is&#xD;
      that similar mechanisms and pathways underlie pulmonary vascular remodeling in IPF-PH,&#xD;
      COPD-PH, and PAH. However, only a subset of Group 3 PH patients display remodeling consistent&#xD;
      with PAH, resulting in responder vs. non-responder phenotypes when treated with PAH-specific&#xD;
      therapies. In preliminary studies of subjects treated with Tyvaso, The study team has&#xD;
      observed distinct 129Xe MRI signatures at baseline and with therapy depending on patients'&#xD;
      underlying lung function. Consistent with this, recent studies using single-cell RNA&#xD;
      sequencing (scRNAseq) of the pulmonary vasculature in IPF have demonstrated changes&#xD;
      consistent with vascular remodeling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a pathology-based 129Xe MRI noninvasive signature of pulmonary vascular remodeling that could be validated in a larger cohort of Group 3 PH patients</measure>
    <time_frame>2 yrs</time_frame>
    <description>Such a signature could then be tested in clinical trials in Group 3 PH. These studies will have an important positive impact because they lay the foundation for a precision medicine strategy in Group 3 PH through the identification of potential responders and non-responders to PAH-specific therapies</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>COPD</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>PAH:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease or other causes of non-Group 1 PH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD-noPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical diagnosis of COPD in the absence of precapillary PH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD-PH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical diagnosis of COPD with precapillary PH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPF-noPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical diagnosis of IPF in the absence of precapillary PH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPF-PH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical diagnosis of IPF with precapillary PH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized 129Xe</intervention_name>
    <description>Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),</description>
    <arm_group_label>COPD-PH</arm_group_label>
    <arm_group_label>COPD-noPH</arm_group_label>
    <arm_group_label>IPF-PH</arm_group_label>
    <arm_group_label>IPF-noPH</arm_group_label>
    <arm_group_label>PAH:</arm_group_label>
    <other_name>Xe MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years' old&#xD;
&#xD;
          2. Be on the lung transplant waiting list at Duke University Medical Center.&#xD;
&#xD;
          3. PH as defined by RHC - mPAP &gt; 20 mmHg, PVR &gt; 3 WU, PCWP &lt; 15 mmHg&#xD;
&#xD;
          4. Groups defined as:&#xD;
&#xD;
             PAH: Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung&#xD;
             disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell&#xD;
             disease, or other causes of non-Group 1 PH.&#xD;
&#xD;
             COPD-noPH: Clinical diagnosis of COPD in the absence of precapillary PH.&#xD;
&#xD;
             COPD-PH: Clinical diagnosis of COPD with precapillary PH.&#xD;
&#xD;
             IPF-noPH: Clinical diagnosis of IPF in the absence of precapillary PH.&#xD;
&#xD;
             IPF-PH: Clinical diagnosis of IPF with precapillary PH.&#xD;
&#xD;
          5. Willing and able to give informed consent and adhere to visit/protocol schedules&#xD;
             (consent must be given before any study procedures are performed).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Moderate to severe heart disease (LVEF &lt; 45% or severe LV Hypertrophy).&#xD;
&#xD;
          2. Sarcoidosis.&#xD;
&#xD;
          3. Active cancer.&#xD;
&#xD;
          4. Sickle cell anemia.&#xD;
&#xD;
          5. Liver disease (Childs-Pugh class C).&#xD;
&#xD;
          6. Prisoners and pregnant women will not be approached for the study.&#xD;
&#xD;
          7. Inability to obtain consent.&#xD;
&#xD;
          8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to&#xD;
             lie supine).&#xD;
&#xD;
          9. Medical or psychological conditions which, in the opinion of the investigator, might&#xD;
             create undue risk to the subject or interfere with the subject's ability to comply&#xD;
             with the protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudarshan Rajagopal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susana Almeida-Peters, BN, RN</last_name>
    <phone>919-668-2642</phone>
    <email>susana.almeida-peters@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha Womack, MS</last_name>
    <phone>919-681-8439</phone>
    <email>sam.womack@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Susana Almeida-Peters, RN</last_name>
      <phone>919-668-2642</phone>
      <email>susana.almeida-peters@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Womack</last_name>
      <phone>919-684-7931</phone>
      <email>Samantha.Womack@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sudarshan Rajagopal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Bastiaan Driehuys</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>Lung Transplant</keyword>
  <keyword>Group 3 PH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

